Quick Takeaways
- Douglas K. Bratton filed SCHEDULE 13G/A for Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST).
- Disclosed ownership: 11%.
- Date of event: 31 Dec 2024.
Douglas K. Bratton - 31 Dec 2024 SCHEDULE 13G/A Report for Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST)
- Filing Manager
- Douglas K. Bratton
- Reporting Manager
- BRATTON DOUGLAS K
- Symbol
- AQST
- Shares outstanding
- 90,787,694 shares
- Disclosed Ownership
- 10,077,434 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2025, 11:38:04 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Douglas K. Bratton disclosed 11% ownership in Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2025, 11:38.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (6)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BRATTON DOUGLAS K | 11% | 10,077,434 | 10,023,384 | 0 | Douglas K. Bratton | Individual | |
| MonoLine RX II, L.P. | 3.8% | 3,468,747 | 3,468,747 | 0 | John Cochran | Vice President of General Partner of General Partner | |
| MonoLine RX III, L.P. | 2.9% | 2,657,943 | 2,657,943 | 0 | John Cochran | Vice President of General Partner of General Partner | |
| MonoLine RX, L.P. | 1.9% | 1,688,639 | 1,688,639 | 0 | John Cochran | Vice President of General Partner of General Partner | |
| MonoLine Partners, L.P. | 2.1% | 1,948,578 | 1,948,578 | 0 | John Cochran | Vice President of General Partner of General Partner | |
| MonoSol Rx Genpar, L.P. | 0.1% | 47,051 | 47,051 | 0 | John Cochran | Vice President of General Partner |